Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export (SINE) Compound Selinexor (KPT-330) in Patients with Relapsed or Refractory AML

被引：8
|
作者：
Fiedler, Walter [1 ]
Heuser, Michael [2 ]
Chromik, Joerg [3 ]
Thol, Felicitas [2 ]
Bokemeyer, Carsten [4 ]
Theile, Susann [5 ]
Lebkuechner, Isabell [5 ]
Kranich, Anne L. [6 ]
机构：
[1] Univ Hosp Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[2] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
[3] Univ Hosp Frankfurt, Frankfurt, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Med Clin & Polyclin 2, Hamburg, Germany
[5] GSOmbH, Hamburg, Germany
[6] GSO Global B V, Amsterdam, Netherlands
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.341.341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
341
引用
收藏
页数：6
相关论文
共 50 条
  • [11] Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)
    Savona, Michael
    Garzon, Ramiro
    Brown, Peter de Nully
    Yee, Karen
    Lancet, Jeffrey E.
    Gutierrez, Martin
    Gabrail, Nashat
    Mau-Sorensen, Morten
    Baz, Rachid
    Byrd, John C.
    Kuruvilla, John
    Siegel, David S.
    Shacham, Sharon
    Rashal, Tami
    Yau, Cindy Y. F.
    McCauley, Dilara
    Saint-Martin, Jean-Richard
    McCartney, John
    Landesman, Yosef
    Klebanov, Boris
    Pond, Greg
    Oza, Amit M.
    Kauffman, Michael
    Mirza, Mansoor R.
    Stone, Richard M.
    BLOOD, 2013, 122 (21)
  • [12] Preclinical efficacy of the novel, oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on castration resistant prostate cancer
    Maity, Sankar Narayan
    Wu, Guanglin
    Lu, Jing-Fang
    Hoang, Anh
    Landesman, Yosef
    McCauley, Dilara
    Shacham, Sharon
    Kauffman, Michael G.
    Aparicio, Ana M.
    Efstathiou, Eleni
    Araujo, John C.
    Logothetis, Christopher J.
    CANCER RESEARCH, 2014, 74 (19)
  • [13] Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors.
    Marks, Lianna Jean
    Diolaiti, Daniel
    Mundi, Prabhjot Singh
    Gaviria, Ervin
    Rainey, Allison
    Dela Cruz, Filemon
    Califano, Andrea
    Kung, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
    J Etchin
    J Montero
    A Berezovskaya
    B T Le
    A Kentsis
    A L Christie
    A S Conway
    W C Chen
    C Reed
    M R Mansour
    C E L Ng
    S Adamia
    S J Rodig
    I A Galinsky
    R M Stone
    B Klebanov
    Y Landesman
    M Kauffman
    S Shacham
    A L Kung
    J C Y Wang
    A Letai
    A T Look
    Leukemia, 2016, 30 : 0 - 0
  • [15] KCP-330-005/SIGN: A PHASE II, OPEN-LABEL STUDY OF EFFICACY AND SAFETY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) KPT-330 (SELINEXOR) IN PATIENTS WITH ADVANCED GYNAECOLOGIC MALIGNANCIES
    Vergote, I.
    Lund, B.
    Ujmajuridze, Z.
    Havsteen, H.
    Rashal, T.
    Marshall, T.
    McCartney, J.
    Kauffman, M.
    Shacham, S.
    Mirza, M. R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1182 - 1183
  • [16] Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
    Etchin, J.
    Montero, J.
    Berezovskaya, A.
    Le, B. T.
    Kentsis, A.
    Christie, A. L.
    Conway, A. S.
    Chen, W. C.
    Reed, C.
    Mansour, M. R.
    Ng, C. E. L.
    Adamia, S.
    Rodig, S. J.
    Galinsky, I. A.
    Stone, R. M.
    Klebanov, B.
    Landesman, Y.
    Kauffman, M.
    Shacham, S.
    Kung, A. L.
    Wang, J. C. Y.
    Letai, A.
    Look, A. T.
    LEUKEMIA, 2016, 30 (01) : 190 - 199
  • [17] Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML
    Rubnitz, Jeffrey E.
    Kaufman, Ronda
    Ribeiro, Raul C.
    Klebanov, Boris
    Ellis, Joel
    Landesman, Yosef
    Youssoufian, Hagop
    Rashal, Tami
    Shacham, Sharon
    BLOOD, 2015, 126 (23)
  • [18] THE COMBINATION OF SELINEXOR (KPT-330), A SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), & THE FLT3 INHIBITOR QUIZATINIB SHOWS ANTI-TUMOR ACTIVITY IN ACUTE MYELOID LEUKEMIA (AML) IN VITRO AND IN VIVO
    Carlson, R.
    Senapedis, W.
    Landesman, Y.
    Shacham, S.
    HAEMATOLOGICA, 2014, 99 : 290 - 291
  • [19] Selinexor (KPT-330), a novel selective inhibitor of nuclear export (SINE), shows single agent efficacy against alveolar soft part sarcoma (ASPS) in vivo
    Crochiere, Marsha L.
    Kashyap, Trinayan
    Klebanov, Boris
    Senapedis, William
    del Alamo, Diego
    Tamir, Sharon
    Baloglu, Erkan
    McCauley, Dilara
    Carlson, Robert
    Kauffman, Michael
    Shacham, Sharon
    Demetri, George
    Wagner, Andrew
    Sicinska, Ewa
    Gokhale, Prafulla
    Kohl, Nancy
    Saur, Amy
    Landesman, Yosef
    CANCER RESEARCH, 2014, 74 (19)
  • [20] A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas.
    Gounder, Mrinal M.
    Loong, Herbert H. F.
    Nyquist-Schultz, Kjirsten
    Baker, Stephanie
    Ustoyev, Yelena
    Tanner, Lanier R.
    Shacham, Sharon
    McCauley, Dilara
    Rashal, Tami
    Saint-Martin, Jean-Richard
    Shacham, Eran
    Friedlander, Sharon
    Tamir, Sharon
    Marshall, Tracey
    Landesman, Yosef
    Kauffman, Michael
    Rebello, Sasha
    Mirza, Mansoor Slide Raza
    Schwartz, Gary K.
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345